Evidence map›Paper›PMID 37989512›Full record

ArticleCMAJ open

SARS-CoV-2 vaccination prevalence by mental health diagnosis: a population-based cross-sectional study in Ontario, Canada.

Paul Kurdyak, Michael Lebenbaum, Aditi Patrikar, Laura Rivera, Hong Lu, Damon C Scales, Astrid Guttmann

Abstract read
In one paragraph

Article in CMAJ open. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Paul KurdyakICES Central (Kurdyak, Lebenbaum, Patrikar, Lu, Scales, Guttmann); Centre for Addiction and Mental Health (Kurdyak); Institute of Health Policy Management and Evaluation (Kurdyak, Lebenbaum, Scales), and Departments of Psychiatry (Rivera) and Paediatrics (Guttmann), and Edwin S.H. Leong Centre for Healthy Children (Guttmann), University of Toronto, Toronto, Ont. paul.kurdyak@camh.ca.
Michael LebenbaumICES Central (Kurdyak, Lebenbaum, Patrikar, Lu, Scales, Guttmann); Centre for Addiction and Mental Health (Kurdyak); Institute of Health Policy Management and Evaluation (Kurdyak, Lebenbaum, Scales), and Departments of Psychiatry (Rivera) and Paediatrics (Guttmann), and Edwin S.H. Leong Centre for Healthy Children (Guttmann), University of Toronto, Toronto, Ont.
Aditi PatrikarICES Central (Kurdyak, Lebenbaum, Patrikar, Lu, Scales, Guttmann); Centre for Addiction and Mental Health (Kurdyak); Institute of Health Policy Management and Evaluation (Kurdyak, Lebenbaum, Scales), and Departments of Psychiatry (Rivera) and Paediatrics (Guttmann), and Edwin S.H. Leong Centre for Healthy Children (Guttmann), University of Toronto, Toronto, Ont.
Laura RiveraICES Central (Kurdyak, Lebenbaum, Patrikar, Lu, Scales, Guttmann); Centre for Addiction and Mental Health (Kurdyak); Institute of Health Policy Management and Evaluation (Kurdyak, Lebenbaum, Scales), and Departments of Psychiatry (Rivera) and Paediatrics (Guttmann), and Edwin S.H. Leong Centre for Healthy Children (Guttmann), University of Toronto, Toronto, Ont.
Hong LuICES Central (Kurdyak, Lebenbaum, Patrikar, Lu, Scales, Guttmann); Centre for Addiction and Mental Health (Kurdyak); Institute of Health Policy Management and Evaluation (Kurdyak, Lebenbaum, Scales), and Departments of Psychiatry (Rivera) and Paediatrics (Guttmann), and Edwin S.H. Leong Centre for Healthy Children (Guttmann), University of Toronto, Toronto, Ont.
Damon C ScalesICES Central (Kurdyak, Lebenbaum, Patrikar, Lu, Scales, Guttmann); Centre for Addiction and Mental Health (Kurdyak); Institute of Health Policy Management and Evaluation (Kurdyak, Lebenbaum, Scales), and Departments of Psychiatry (Rivera) and Paediatrics (Guttmann), and Edwin S.H. Leong Centre for Healthy Children (Guttmann), University of Toronto, Toronto, Ont.
Astrid GuttmannICES Central (Kurdyak, Lebenbaum, Patrikar, Lu, Scales, Guttmann); Centre for Addiction and Mental Health (Kurdyak); Institute of Health Policy Management and Evaluation (Kurdyak, Lebenbaum, Scales), and Departments of Psychiatry (Rivera) and Paediatrics (Guttmann), and Edwin S.H. Leong Centre for Healthy Children (Guttmann), University of Toronto, Toronto, Ont.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSince the onset of the COVID-19 pandemic, there has been concern about the impact of SARS-CoV-2 infection among individuals with mental illnesses. We analyzed the SARS-CoV-2 vaccination status of Ontarians with and without a history of mental illness.

methodsWe conducted a population-based cross-sectional study of all community-dwelling Ontario residents aged 19 years and older as of Sept. 17, 2021. We used health administrative data to categorize Ontario residents with a mental disorder (anxiety, mood, substance use, psychotic or other disorder) within the previous 5 years. Vaccine receipt as of Sept. 17, 2021, was compared between individuals with and without a history of mental illness.

resultsOur sample included 11 900 868 adult Ontario residents. The proportion of individuals not fully vaccinated (2 doses) was higher among those with substance use disorders (37.7%) or psychotic disorders (32.6%) than among those with no mental disorders (22.9%), whereas there were similar proportions among those with anxiety disorders (23.5%), mood disorders (21.5%) and other disorders (22.1%). After adjustment for age, sex, neighbourhood income and homelessness, individuals with psychotic disorders (adjusted prevalence ratio 1.19, 95% confidence interval [CI] 1.18-1.20) and substance use disorders (adjusted prevalence ratio 1.35, 95% CI 1.34-1.35) were more likely to be partially vaccinated or unvaccinated relative to individuals with no mental disorders.

interpretationOur study found that psychotic disorders and substance use disorders were associated with an increased prevalence of being less than fully vaccinated. Efforts to ensure such individuals have access to vaccinations, while challenging, are critical to ensuring the ongoing risks of death and other adverse consequences of SARS-CoV-2 infection are mitigated in this high-risk population.

Identifiers

PMID37989512
PMCPMC10681672

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.